Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8008338 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2027
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8906950 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(7 months from now) | |
US9216167 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(7 months from now) | |
US8946281 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(7 months from now) | |
US8207215 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(7 months from now) | |
US8541463 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(7 months from now) | |
US8377982 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(7 months from now) | |
US8648107 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(7 months from now) | |
US8541463 (Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(1 year, 2 months from now) | |
US8207215 (Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(1 year, 2 months from now) | |
US8377982 (Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(1 year, 2 months from now) | |
US8008338 (Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2027
(4 years from now) |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: A method of treating or preventing ocular pain and burning; A method of treating ocular pain and/or enhancing ocular comfort; A method of treating ocular pain; A method of controlling postoperative oc...
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7842714 | ALLERGAN | Ketorolac tromethamine compositions for treating ocular pain |
Aug, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8992952 | ALLERGAN | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Aug, 2024
(10 months from now) | |
US8512717 | ALLERGAN | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Mar, 2028
(4 years from now) | |
US9192571 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Mar, 2028
(4 years from now) |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 22 July, 2009
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6562873 (Pediatric) | ALLERGAN | Compositions containing therapeutically active components having enhanced solubility |
Jan, 2022
(1 year, 8 months ago) | |
US9295641 (Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 8 months ago) | |
US9687443 (Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 8 months ago) | |
US6627210 (Pediatric) | ALLERGAN | Compositions containing α-2-adrenergic agonist components |
Jan, 2022
(1 year, 8 months ago) | |
US6673337 (Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 8 months ago) | |
US6641834 (Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 7 months ago) | |
US8858961 | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Sep, 2023
(26 days ago) | |
US8858961 (Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Mar, 2024
(5 months from now) |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 19 August, 2005
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7112592 | ALLERGAN | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
Jan, 2026
(2 years from now) | |
US8471025 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Aug, 2031
(7 years from now) | |
US9695122 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(8 years from now) | |
US9284314 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(8 years from now) | |
US8969566 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7612087 | ALLERGAN | Heterocyclic compounds as inhibitors of beta-lactamases |
Nov, 2026
(3 years from now) | |
US8835455 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Oct, 2030
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 25, 2020 |
New Patient Population (NPP) | Dec 20, 2025 |
Generating Antibiotic Incentives Now (GAIN) | Feb 25, 2025 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: 2024-02-26
Market Authorisation Date: 25 February, 2015
Treatment: A method of treating bacterial infections in complicated intra-abdominal infection and complicated urinary tract infection, including pyelonephritis, patients comprising administering a bactericidally...
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7803838 | ALLERGAN | Compositions comprising nebivolol |
Aug, 2026
(2 years from now) | |
US7838552 | ALLERGAN | Compositions comprising nebivolol |
Oct, 2027
(4 years from now) |
Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient
Market Authorisation Date: 03 June, 2016
Treatment: Method of treating hypertension
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8217083 | ALLERGAN | Mesalamine suppository |
Jun, 2028
(4 years from now) | |
US8436051 | ALLERGAN | Mesalamine suppository |
Jun, 2028
(4 years from now) |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 05 January, 2001
Treatment: NA
Dosage: SUPPOSITORY;RECTAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7642258 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 5 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9474751 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 5 months ago) | |
US7320976 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 5 months ago) | |
US8133890 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 5 months ago) | |
US9770453 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 5 months ago) | |
US8354409 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 5 months ago) | |
US8748425 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 5 months ago) | |
US9907802 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 5 months ago) | |
US7030149 | ALLERGAN | Combination of brimonidine timolol for topical ophthalmic use |
Apr, 2022
(1 year, 5 months ago) | |
US9907801 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 5 months ago) | |
US7323463 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Jan, 2023
(8 months ago) |
Drugs and Companies using BRIMONIDINE TARTRATE; TIMOLOL MALEATE ingredient
Market Authorisation Date: 30 October, 2007
Treatment: Reduction of elevated intraocular pressure; Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inade...
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8143212 | ALLERGAN | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(a month from now) | |
US7115564 | ALLERGAN | Stable pharmaceutical compositions of dalbavancin and methods of administration |
Nov, 2023
(a month from now) | |
US7119061 | ALLERGAN | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(a month from now) | |
US6900175 | ALLERGAN | Methods of administering dalbavancin for treatment of bacterial infections |
May, 2028
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 23, 2019 |
New Patient Population (NPP) | Jul 22, 2024 |
Generating Antibiotic Incentives Now (GAIN) | May 23, 2024 |
Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 2023-05-24
Market Authorisation Date: 23 May, 2014
Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8865937 | ALLERGAN | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide |
May, 2032
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE43879 | ALLERGAN | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug |
Jan, 2026
(2 years from now) | |
US8481598 | ALLERGAN | Stable dosage forms of levomilnacipran |
Mar, 2031
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M (M) | Oct 7, 2022 |
Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient
Market Authorisation Date: 25 July, 2013
Treatment: Treatment of major depressive disorder (mdd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9259388 | ALLERGAN | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(6 years from now) | |
US10449173 | ALLERGAN | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(6 years from now) | |
US8920392 | ALLERGAN | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Mar, 2031
(7 years from now) |
Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient
Market Authorisation Date: 27 January, 2009
Treatment: Treatment of overactive bladder by application of oxybutynin chloride gel to skin; Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence wi...
Dosage: GEL;TRANSDERMAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7198801 | ALLERGAN | Formulations for transdermal or transmucosal application |
Jun, 2022
(1 year, 3 months ago) |
Drugs and Companies using OXYBUTYNIN ingredient
Market Authorisation Date: 07 December, 2011
Treatment: NA
Dosage: GEL, METERED;TRANSDERMAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10617695 | ALLERGAN | Ophthalmic compositions containing alcaftadine |
Mar, 2027
(3 years from now) | |
US8664215 | ALLERGAN | Ocular allergy treatments with alcaftadine |
Dec, 2027
(4 years from now) |
Drugs and Companies using ALCAFTADINE ingredient
Market Authorisation Date: 28 July, 2010
Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8038988 | ALLERGAN | Method of enhancing hair growth |
Aug, 2023
(a month ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8758733 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(8 months ago) | |
US9216183 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(8 months ago) | |
US8263054 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(8 months ago) | |
US8986715 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(8 months ago) | |
US9226931 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(8 months ago) | |
US8632760 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(8 months ago) | |
US8101161 | ALLERGAN | Method of enhancing hair growth |
May, 2024
(7 months from now) |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 24 December, 2008
Treatment: Method of increasing eyelash growth; Method of increasing eyelash growth including length, thickness, darkness and/or number of eyelashes by administering bimatoprost to an eyelid margin; Method of in...
Dosage: SOLUTION/DROPS;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6916941 | ALLERGAN | Crystalline composition containing escitalopram |
Aug, 2022
(1 year, 1 month ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7420069 | ALLERGAN | Crystalline composition containing escitalopram |
Aug, 2022
(1 year, 1 month ago) | |
US6916941 (Pediatric) | ALLERGAN | Crystalline composition containing escitalopram |
Feb, 2023
(7 months ago) | |
US7420069 (Pediatric) | ALLERGAN | Crystalline composition containing escitalopram |
Feb, 2023
(7 months ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | May 12, 2026 |
Drugs and Companies using ESCITALOPRAM OXALATE ingredient
Market Authorisation Date: 14 August, 2002
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7704947 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(3 months from now) | |
US7745409 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(3 months from now) | |
US8080526 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(3 months from now) | |
US7371727 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(3 months from now) | |
US7304036 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Aug, 2026
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8110553 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(3 months from now) | |
US8933030 | ALLERGAN | Treatments for gastrointestinal disorders |
Feb, 2031
(7 years from now) | |
US10702576 | ALLERGAN | Stable formulations of linaclotide |
Aug, 2031
(7 years from now) | |
US10675325 | ALLERGAN | Stable formulations of linaclotide |
Aug, 2031
(7 years from now) | |
US8748573 | ALLERGAN | Formulations comprising linaclotide |
Oct, 2031
(8 years from now) | |
US8802628 | ALLERGAN | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
Oct, 2031
(8 years from now) | |
US9708371 | ALLERGAN | Treatments for gastrointestinal disorders |
Aug, 2033
(9 years from now) |
Drugs and Companies using LINACLOTIDE ingredient
Market Authorisation Date: 30 August, 2012
Treatment: Method of treating irritable bowel syndrome with constipation in adults; Method of treating chronic idiopathic constipation in adult patients.; Method of treating irritable bowel syndrome with constip...
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7851504 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Jun, 2027
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8933120 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 5 months from now) | |
US8524777 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 5 months from now) | |
US9241918 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 5 months from now) | |
US8299118 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 5 months from now) | |
US8309605 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 5 months from now) | |
US8772338 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 5 months from now) | |
US8338479 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 5 months from now) | |
US9155716 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 5 months from now) | |
US8586630 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 5 months from now) | |
US8278353 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 5 months from now) | |
US8933127 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 5 months from now) |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 31 August, 2010
Treatment: Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; Method of treating glaucoma or elevated intraocular pressure; A method of treating a patient with glaucoma ...
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8039009 | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(5 years from now) | |
US8039009 (Pediatric) | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(5 years from now) |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 June, 2010
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8338485 | ALLERGAN | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
US8173708 | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
US8362085 | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
US8338486 | ALLERGAN | Methods for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
US8283379 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
US8580858 | ALLERGAN | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
US8329752 | ALLERGAN | Composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
US8598233 | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
US8168209 | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
US8293794 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
US8173708 (Pediatric) | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8283379 (Pediatric) | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
May, 2026
(2 years from now) | |
US8329752 (Pediatric) | ALLERGAN | Composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8362085 (Pediatric) | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8168209 (Pediatric) | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8598233 (Pediatric) | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8039009 | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(5 years from now) | |
US8039009 (Pediatric) | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(5 years from now) | |
US8058291 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Dec, 2029
(6 years from now) |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 December, 2014
Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8506987 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(8 months ago) | |
US8034366 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(8 months ago) | |
US10702539 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(8 months ago) | |
US9192511 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(8 months ago) | |
US8034370 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(8 months ago) | |
US10076526 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(8 months ago) | |
US6899717 | ALLERGAN | Methods and apparatus for delivery of ocular implants |
Nov, 2023
(a month from now) |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 17 June, 2009
Treatment: Treatment of macular edema; Treatment of uveitis; Treatment of diabetic macular edema; Treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo...
Dosage: IMPLANT;INTRAVITREAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8648048 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(10 months from now) | |
US8642556 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(10 months from now) | |
US8629111 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(10 months from now) | |
US8685930 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(10 months from now) | |
US9248191 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(10 months from now) | |
US8633162 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(10 months from now) | |
US8292129 | ALLERGAN | Dispensing device |
Feb, 2031
(7 years from now) | |
US8561859 | ALLERGAN | Dispensing device |
Apr, 2032
(8 years from now) | |
US9676525 | ALLERGAN | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
Feb, 2034
(10 years from now) | |
US9669974 | ALLERGAN | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
May, 2034
(10 years from now) |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).; Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7741358 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(2 years from now) | |
US8022228 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7741358 (Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(3 years from now) | |
US8022228 (Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(3 years from now) |
Drugs and Companies using ASENAPINE MALEATE ingredient
Market Authorisation Date: 13 August, 2009
Treatment: Use of the atypical antipsychotic asenapine for treatment of schizophrenia in adults; Treatment of bipolar disorder and schizophrenia; Use of the atypical antipsychotic asenapine for treatment of mani...
Dosage: TABLET;SUBLINGUAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6602911 | ALLERGAN | Methods of treating fibromyalgia |
Jan, 2023
(8 months ago) | |
US7994220 | ALLERGAN | Milnacipran for the long-term treatment of fibromyalgia syndrome |
Sep, 2029
(5 years from now) |
Drugs and Companies using MILNACIPRAN HYDROCHLORIDE ingredient
Market Authorisation Date: 14 January, 2009
Treatment: Management of fibromyalgia (fm); Management of fibromyalgia
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6417175 | ALLERGAN | Phosphonocephem derivatives, process for the preparation of the same, and use thereof |
Apr, 2022
(1 year, 5 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9629861 | ALLERGAN | Compositions and methods for treating bacterial infections using ceftaroline |
Sep, 2030
(6 years from now) | |
US8247400 | ALLERGAN | Cephem compounds useful for the treatment of bacterial infections |
Feb, 2031
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Sep 13, 2022 |
Drugs and Companies using CEFTAROLINE FOSAMIL ingredient
Market Authorisation Date: 29 October, 2010
Treatment: Method of treating bacterial infections; Methods for treating bacterial infections
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8912210 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(8 years from now) | |
US9499545 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(8 years from now) | |
US8754096 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9833448 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(8 years from now) | |
US10117836 | ALLERGAN | Tablet formulation for CGRP active compounds |
Jan, 2035
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 2023-12-24
Market Authorisation Date: 23 December, 2019
Treatment: Acute treatment of migraine with or without aura in adults; Acute treatment of migraine with headache, with or without aura in adults
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7834020 | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(1 year, 3 months ago) | |
US8673921 | ALLERGAN | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(1 year, 3 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8236804 | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Jun, 2022
(1 year, 3 months ago) | |
US8193195 | ALLERGAN | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(1 year, 3 months ago) | |
US8193195 (Pediatric) | ALLERGAN | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(9 months ago) | |
US8236804 (Pediatric) | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Dec, 2022
(9 months ago) | |
US7834020 (Pediatric) | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(9 months ago) | |
US8673921 (Pediatric) | ALLERGAN | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(9 months ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M (M) | Jan 31, 2023 |
Pediatric Exclusivity (PED) | Jul 31, 2023 |
Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 January, 2011
Treatment: Treatment of major depressive disorder (mdd)
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7943621 | ALLERGAN | Salts of piperazine compounds as D3/D2 antagonists |
Dec, 2028
(5 years from now) | |
US7737142 | ALLERGAN | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists |
Sep, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE47350 | ALLERGAN | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(5 years from now) | |
USRE49110 | ALLERGAN | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication (I) | Dec 16, 2025 |
Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 September, 2015
Treatment: Treatment of schizophrenia and/or acute manic or mixed episodes associated with bipolar i disorder with cariprazine; Treatment of schizophrenia with cariprazine; Treatment of acute manic or mixed epis...
Dosage: CAPSULE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic